A Phase 2 interventional study of QRX-3 in Chronic Kidney Disease Stages 3-5, Diabetic Kidney Disease and Hypertensive Kidney Disease, sponsored by Ebima Clifford Okundaye. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-08.
Sponsored by Ebima Clifford Okundaye · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 153 studies in Diabetic Nephropathies with a site in United States — 22 open to participants now, 32 under way, 1 of them phase 3. Diabetic Nephropathies · United States.
Among the 153 studies in Diabetic Nephropathies with a site in United States, this one is the 44th largest by enrollment of the 120 interventional ones that give a count, is one of 7 that started in 2023, is one of 54 in phase 2, and was the 146th registered.
543 studies on the registry are indexed under Diabetic Nephropathies; 110 are open to participants now.
Browse Diabetic Nephropathies studies →22 of the 153 studies in Diabetic Nephropathies with a site in United States are open now. Recruiting first, the newest first:
Regeneron Pharmaceuticals · Sites in United States
Ages 18–80
Medical University of South Carolina · Sites in United States
Ages 18–75
University of Pennsylvania · Sites in United States
Ages 18+ · Healthy volunteers
AstraZeneca · Sites in United States
Ages 18–75 · Healthy volunteers
Seattle Children's Hospital · Sites in United States
Ages 14–40
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 50 Diabetic Nephropathies studies recruiting now, 23 (46%) set no upper age limit and 16 (32%) stop at 75 or younger; 5 take children under 18; 8 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
153 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 21 · Phase 2 61 · Phase 3 16 · Phase 4 10
First in 1981; this study’s year is marked. 7 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 127 is above the median of 78 across 388 interventional studies indexed under Diabetic Nephropathies.
Median enrollment 79 across the 120 interventional studies, 175 across the 31 observational. Of the 115 that completed or were terminated, 46 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
70 of 153 have an industry lead sponsor. The 10 most frequent:
Ebima Clifford Okundaye is the lead sponsor of 3 studies on the registry; 2 are open to participants now.
Ebima Clifford Okundaye has 1 study filed under Diabetic Nephropathies — fewer than ten, so there is no comparison to draw.
12 of the studies in Diabetic Nephropathies with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05759468Brigham and Women's HospitalNAD Augmentation in Diabetes Kidney Disease | 2026-11-30 |
| NCT07022418Medical University of South CarolinaFormoterol in Diabetes | 2026-12 |
| NCT04802395Renalytix AI, Inc.Real World Evidence Clinical Utility Study of KidneyIntelX | 2026-12-01 |
| NCT05507892University of Colorado, DenverRenal Mechanism of SGLT2 Inhibition | 2026-12-15 |
| NCT07024823AstraZenecaA Study to Investigate Safety, Tolerability, PK, and PD of AZD4248 in Healthy Participants, Participants With CKD and Type 2 Diabetes, Assess Home Measurements of Creatinine in a Non-Interventional Cohort, and Assess the Effect of AZD4248 on the PK of Midazolam and Metformin in Healthy Participants | 2027-01-29 |
Add all 12 to your calendar (.ics) → With an account.
Among the 153 studies in Diabetic Nephropathies with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
QRX-3, a new drug that stabilized the kidney renal tubular cell and increase the activity of NAD ( nicotinamide adenine dineuclotide )within the kidney cells; leading to decrease oxidative changes intracellularly, repair of renal tubular injury and restoration of optimized renal function above baseline , will be studied in patients with progressive chronic kidney disease over 12 months . The result of the change in renal function expressed as creatinine GFR (Glomerular filtration decline) over the treatment duration will be compared in the treatment group will be compared to control group without the medication during that same period .
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
control group - continued on standard therapy for CKD
QRX-3 drug given in addition to standard therapy for CKD
Drug: QRX-3
phase 2B CKD study
daily change in glomerular filtration rate by creatinine in mls/min
mean change in glomerular filtration rate by creatinine in mls/min in one year compare to baseline at screening
Time frame: 12 months
change in proteinuria by mg/g
change in mean proteinuria measured by random urine protein/creatinine ratio at 12 months compare to control will be compared in both groups
Time frame: 12 months
Plan to share: Yes — if requested , deidentifiable data can be shared
Supporting information: Clinical study report
Time frame: 4/21/2025 to 10/21/2025
No publications or documents are linked to this record.
Ran from Mar 2023 to primary completion in Aug 2024, 17 months.
Of 32 industry-sponsored phase 2 interventional studies under Diabetic Nephropathies, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 28. This study's 17 months is below that.
Counting every sponsor, half of 52 studies reached it within 21 months; a quarter within 13 and three quarters within 31.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ebima Clifford Okundaye